United States

Core FFO (TTM)

Core FFO/share (TTM)

Core FFO/share Guidance

Core FFO (Quarter)

Core FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/Core FFO

Same Property Occupancy

Centerspace is a real estate company focused on the ownership, management, acquisition, redevelopment, and development of apartment communities. Over the past several years, we have extensively repositioned our portfolio from a diversified, multi-segment collection of properties into a single segment
concentrated on apartment communities. Our current emphasis is on making operational enhancements that will improve our residents' experience, redeveloping
some of our existing apartment communities to meet current market demands, and acquiring new apartment communities.



Centerspace

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2022 Q3

Years since IPO: 15/15,
Core FFO Growth: 10/15,
Core FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2022 Q4

Years since IPO: 15/15,
Core FFO Growth: 13/15,
Core FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2023 Q1

Years since IPO: 15/15,
Core FFO Growth: 10/15,
Core FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2023 Q2

Years since IPO: 15/15,
Core FFO Growth: 10/15,
Core FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2023 Q3

Years since IPO: 15/15,
Core FFO Growth: 10/15,
Core FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 5/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Core FFO Growth: 13/15,
Core FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Core FFO Growth: 15/15,
Core FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Core FFO Growth: 15/15,
Core FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Core FFO Growth: 15/15,
Core FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Core FFO Growth: 15/15,
Core FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 10/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Core FFO Growth: 15/15,
Core FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 5/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Core FFO Growth: 15/15,
Core FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 5/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Core FFO

Core FFO Growth

Assessment of recent increases in Core FFO per share, indicating profitability

Core FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MINNEAPOLIS , Aug. 13, 2025 /PRNewswire/ -- Centerspace (NYSE: CSR) published its 2024 Environmental, Social, and Governance (ESG) Report, and its inaugural Task Force on Climate Related Financial Disclosures (TCFD) report, highlighting the company's commitment to sustainable business practices in the multifamily industry. This is the Company's sixth annual report following its 2019 formation of an Environmental, Social, and Governance Committee established to lead identification, implementation, and tracking the progress of various sustainability initiatives.

CENTERSPACE ANNOUNCES SIXTH ANNUAL ENVIRONMENTAL, SOCIAL, AND GOVERNANCE REPORT

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has received the clinical study report (CSR) for the trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-MS in Healthy Adult Participants.” The CSR concludes that there were no safety or tolerability concerns that were identified in healthy participants following treatment with consecutive daily dosing of Lucid-MS.

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

MINNEAPOLIS , Aug. 4, 2025 /PRNewswire/ -- Centerspace (NYSE: CSR) announced today its financial and operating results for the three and six months ended June 30, 2025. The tables below show Net Loss, Funds from Operations ("FFO")1, and Core FFO1, all on a per diluted share basis, for the three and six months ended June 30, 2025; Same-Store Revenues, Expenses, and Net Operating Income ("NOI")1 over comparable periods; and Same-Store Weighted Average Occupancy, Lease Rate Growth, and Resident Retention for each of the three months ended June 30, 2025, March 31, 2025, and June 30, 2024 and the six months ended June 30, 2025 and 2024.

Centerspace Reports Second Quarter 2025 Financial & Operating Results and Updates 2025 Financial Outlook

MINNEAPOLIS , July 8, 2025 /PRNewswire/ -- Centerspace (NYSE: CSR) will release its operating results for the quarter ended June 30, 2025, after the market closes on Monday, August 4, 2025. Management will host a conference call to discuss those results on Tuesday, August 5, 2025, at 10:00 a.m.

CENTERSPACE ANNOUNCES SECOND QUARTER 2025 EARNINGS RELEASE DATE

The fiber cement market, valued at $14.437B in 2025, is set to grow at a 4.28% CAGR, reaching $17.807B by 2030. Driven by rising construction, eco-friendly demand, and government regulations, the Asia Pacific region leads growth. Key players include James Hardie, Etex, and Nichiha. The fiber cement market, valued at $14.437B in 2025, is set to grow at a 4.28% CAGR, reaching $17.807B by 2030. Driven by rising construction, eco-friendly demand, and government regulations, the Asia Pacific region leads growth. Key players include James Hardie, Etex, and Nichiha.

Fiber Cement Market Outlook Report 2025-2030, with Competitor Profiles for James Hardie Industries, Etex Group, Nichiha, CSR, Gyproc, Everest Industries, Swisspearl, Shera, and Ramco Industries

MINNEAPOLIS , AUG. 13, 2025 /PRNEWSWIRE/ -- CENTERSPACE (NYSE: CSR) PUBLISHED ITS 2024 ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG) REPORT, AND ITS INAUGURAL TASK FORCE ON CLIMATE RELATED FINANCIAL DISCLOSURES (TCFD) REPORT, HIGHLIGHTING THE COMPANY'S COMMITMENT TO SUSTAINABLE BUSINESS PRACTICES IN THE MULTIFAMILY INDUSTRY. THIS IS THE COMPANY'S SIXTH ANNUAL REPORT FOLLOWING ITS 2019 FORMATION OF AN ENVIRONMENTAL, SOCIAL, AND GOVERNANCE COMMITTEE ESTABLISHED TO LEAD IDENTIFICATION, IMPLEMENTATION, AND TRACKING THE PROGRESS OF VARIOUS SUSTAINABILITY INITIATIVES.

TORONTO, AUG. 05, 2025 (GLOBE NEWSWIRE) -- QUANTUM BIOPHARMA LTD. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (QUANTUM BIOPHARMA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO BUILDING A PORTFOLIO OF INNOVATIVE ASSETS AND BIOTECH SOLUTIONS, TODAY ANNOUNCES THROUGH ITS SUBSIDIARY, HUGE BIOPHARMA AUSTRALIA PTY LTD., THAT IT HAS RECEIVED THE CLINICAL STUDY REPORT (CSR) FOR THE TRIAL ENTITLED A PHASE 1, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF LUCID-MS IN HEALTHY ADULT PARTICIPANTS. THE CSR CONCLUDES THAT THERE WERE NO SAFETY OR TOLERABILITY CONCERNS THAT WERE IDENTIFIED IN HEALTHY PARTICIPANTS FOLLOWING TREATMENT WITH CONSECUTIVE DAILY DOSING OF LUCID-MS.

QUANTUM BIOPHARMA ANNOUNCES POSITIVE RESULTS OF THE CLINICAL STUDY REPORT (CSR) FOR THE PHASE 1 MULTIPLE ASCENDING DOSE (MAD) CLINICAL TRIAL OF EXPERIMENTAL MULTIPLE SCLEROSIS DRUG LUCID-21-302 (LUCID-MS)

MINNEAPOLIS , AUG. 4, 2025 /PRNEWSWIRE/ -- CENTERSPACE (NYSE: CSR) ANNOUNCED TODAY ITS FINANCIAL AND OPERATING RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE30, 2025. THE TABLES BELOW SHOW NETLOSS, FUNDS FROM OPERATIONS ("FFO")1, AND CORE FFO1, ALL ON A PER DILUTED SHARE BASIS, FOR THE THREE AND SIX MONTHS ENDED JUNE30, 2025; SAME-STORE REVENUES, EXPENSES, AND NET OPERATING INCOME ("NOI")1 OVER COMPARABLE PERIODS; AND SAME-STORE WEIGHTED AVERAGE OCCUPANCY, LEASE RATE GROWTH, AND RESIDENT RETENTION FOR EACH OF THE THREE MONTHS ENDED JUNE30, 2025, MARCH 31, 2025, AND JUNE30, 2024 AND THE SIX MONTHS ENDED JUNE30, 2025 AND 2024.

CENTERSPACE REPORTS SECOND QUARTER 2025 FINANCIAL & OPERATING RESULTS AND UPDATES 2025 FINANCIAL OUTLOOK

MINNEAPOLIS , JULY 8, 2025 /PRNEWSWIRE/ -- CENTERSPACE (NYSE: CSR) WILL RELEASE ITS OPERATING RESULTS FOR THE QUARTER ENDED JUNE 30, 2025, AFTER THE MARKET CLOSES ON MONDAY, AUGUST 4, 2025. MANAGEMENT WILL HOST A CONFERENCE CALL TO DISCUSS THOSE RESULTS ON TUESDAY, AUGUST 5, 2025, AT 10:00 A.M.

THE FIBER CEMENT MARKET, VALUED AT $14.437B IN 2025, IS SET TO GROW AT A 4.28% CAGR, REACHING $17.807B BY 2030. DRIVEN BY RISING CONSTRUCTION, ECO-FRIENDLY DEMAND, AND GOVERNMENT REGULATIONS, THE ASIA PACIFIC REGION LEADS GROWTH. KEY PLAYERS INCLUDE JAMES HARDIE, ETEX, AND NICHIHA. THE FIBER CEMENT MARKET, VALUED AT $14.437B IN 2025, IS SET TO GROW AT A 4.28% CAGR, REACHING $17.807B BY 2030. DRIVEN BY RISING CONSTRUCTION, ECO-FRIENDLY DEMAND, AND GOVERNMENT REGULATIONS, THE ASIA PACIFIC REGION LEADS GROWTH. KEY PLAYERS INCLUDE JAMES HARDIE, ETEX, AND NICHIHA.

FIBER CEMENT MARKET OUTLOOK REPORT 2025-2030, WITH COMPETITOR PROFILES FOR JAMES HARDIE INDUSTRIES, ETEX GROUP, NICHIHA, CSR, GYPROC, EVEREST INDUSTRIES, SWISSPEARL, SHERA, AND RAMCO INDUSTRIES

BEACHWOOD, OHIO--(BUSINESS WIRE)--MASTERBRAND, INC. (NYSE: MBC, THE COMPANY, OR MASTERBRAND), THE LARGEST RESIDENTIAL CABINET MANUFACTURER IN NORTH AMERICA, TODAY RELEASED THE COMPANY'S ANNUAL CORPORATE SUSTAINABILITY AND RESPONSIBILITY (CSR) REPORT. THIS IS THE THIRD YEAR THE COMPANY HAS PROVIDED AN OVERVIEW OF MASTERBRAND'S PROGRESS IN MANY AREAS OF SUSTAINABILITY AND RESPONSIBILITY, INCLUDING RESOURCE STEWARDSHIP, ASSOCIATE WELLBEING AND CORPORATE GOVERNANCE STRUCTURE. AS AN INDUSTRY LE.

MASTERBRAND RELEASES THIRD ANNUAL CORPORATE SUSTAINABILITY AND RESPONSIBILITY (CSR) REPORT

MINNEAPOLIS , JUNE 2, 2025 /PRNEWSWIRE/ -- CENTERSPACE (NYSE:CSR) (THE "COMPANY") ANNOUNCED THAT ON MAY 30, 2025, IT CLOSED ON THE ACQUISITION OF ITS FIRST COMMUNITY IN SALT LAKE CITY, UT, FOR $149 MILLION. CENTERSPACE HAS ALSO SIGNED AN AGREEMENT TO ACQUIRE A COMMUNITY IN FORT COLLINS, CO, WITH CLOSING ANTICIPATED IN MID-JUNE.

CENTERSPACE ANNOUNCES ENTRANCE INTO THE SALT LAKE CITY MARKET, PLANNED PORTFOLIO TRANSACTIONS, AND QUARTERLY DIVIDEND

MINNEAPOLIS , MAY 1, 2025 /PRNEWSWIRE/ -- CENTERSPACE (NYSE: CSR) ANNOUNCED TODAY ITS FINANCIAL AND OPERATING RESULTS FOR THE THREE MONTHS ENDED MARCH31, 2025. THE TABLES BELOW SHOW NETLOSS, FUNDS FROM OPERATIONS ("FFO")1, AND CORE FFO1, ALL ON A PER DILUTED SHARE BASIS, FOR THE THREE MONTHS ENDED MARCH31, 2025; SAME-STORE REVENUES, EXPENSES, AND NET OPERATING INCOME ("NOI")1 OVER COMPARABLE PERIODS; AND SAME-STORE WEIGHTED AVERAGE OCCUPANCY, LEASE RATE GROWTH, AND RESIDENT RETENTION FOR EACH OF THE THREE MONTHS ENDED MARCH31, 2025, DECEMBER 31, 2024, AND MARCH31, 2024.

CENTERSPACE REPORTS FIRST QUARTER 2025 FINANCIAL & OPERATING RESULTS AND REAFFIRMS 2025 CORE FFO PER SHARE GUIDANCE

ATOS ANNOUNCES THE APPOINTMENT OF MARIE DE SCORBIAC AS HEAD OF INVESTOR RELATIONS AND CSR

MINNEAPOLIS , APRIL 1, 2025 /PRNEWSWIRE/ -- CENTERSPACE (NYSE: CSR) WILL RELEASE ITS OPERATING RESULTS FOR THE QUARTER ENDED MARCH 31, 2025, AFTER THE MARKET CLOSES ON THURSDAY, MAY 1, 2025. MANAGEMENT WILL HOST A CONFERENCE CALL TO DISCUSS THOSE RESULTS ON FRIDAY, MAY 2, 2025, AT 1:00 P.M.

Centerspace

CSR

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

CSR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

CSR